INTRODUCTION: This is a report on urinary function results from a randomized trial of nightly versus on-demand sildenafilafter nerve-sparing radical prostatectomy (RP), a secondary objective. We analyzed the effects of these sildenafil administration schemes on urinary health-related quality of life after RP. METHODS: In total, 100 potent men were equally randomized to nightly and on-demand sildenafil 50 mg after minimally-invasive RP for 1 year. Health-related quality of life questionnaires were administered at various postoperative intervals. Urinary function was assessed using appropriate expanded prostate cancer index composite (EPIC) subscales. Analyses of covariance and linear mixed-effects modeling were used to compare the effects of treatment over time on urinary recovery, controlling for age, nerve-sparing score, and time from surgery. RESULTS: The nightly (n = 50) and on-demand (n = 50) sildenafil groups were well-matched at baseline. Nightly sildenafil patients had worse EPIC urinary bother and urinary irritative/obstructive subscale scores at 3 and 6 months after RP, even after controlling for multiple variables. On mixed-model analyses, the differences between groups for these EPIC subscales (4.9 and 2.5, respectively) were greater than documented thresholds for clinical significance. Increasing nerve-sparing score was associated with improvements in EPIC urinary summary, bother, incontinence, and function scores; time from surgery was associated with improvements in all EPIC urinary health-related quality of life subscales. CONCLUSIONS: In this specific population and drug dose, we found that on-demand short-acting phosphodiesterase-5 inhibitor (PDE5i) dosing may be more effective after RP to maximize early urinary health-related quality of life. In preoperatively potent men, nightly sildenafil 50 mg impaired urinary health-related quality of life more than on-demand use in the early months after nerve-sparing RP, independent of effects on urinary continence.
RCT Entities:
INTRODUCTION: This is a report on urinary function results from a randomized trial of nightly versus on-demand sildenafil after nerve-sparing radical prostatectomy (RP), a secondary objective. We analyzed the effects of these sildenafil administration schemes on urinary health-related quality of life after RP. METHODS: In total, 100 potent men were equally randomized to nightly and on-demand sildenafil 50 mg after minimally-invasive RP for 1 year. Health-related quality of life questionnaires were administered at various postoperative intervals. Urinary function was assessed using appropriate expanded prostate cancer index composite (EPIC) subscales. Analyses of covariance and linear mixed-effects modeling were used to compare the effects of treatment over time on urinary recovery, controlling for age, nerve-sparing score, and time from surgery. RESULTS: The nightly (n = 50) and on-demand (n = 50) sildenafil groups were well-matched at baseline. Nightly sildenafilpatients had worse EPIC urinary bother and urinary irritative/obstructive subscale scores at 3 and 6 months after RP, even after controlling for multiple variables. On mixed-model analyses, the differences between groups for these EPIC subscales (4.9 and 2.5, respectively) were greater than documented thresholds for clinical significance. Increasing nerve-sparing score was associated with improvements in EPIC urinary summary, bother, incontinence, and function scores; time from surgery was associated with improvements in all EPIC urinary health-related quality of life subscales. CONCLUSIONS: In this specific population and drug dose, we found that on-demand short-acting phosphodiesterase-5 inhibitor (PDE5i) dosing may be more effective after RP to maximize early urinary health-related quality of life. In preoperatively potent men, nightly sildenafil 50 mg impaired urinary health-related quality of life more than on-demand use in the early months after nerve-sparing RP, independent of effects on urinary continence.
Authors: Gunnar Steineck; Anders Bjartell; Jonas Hugosson; Elin Axén; Stefan Carlsson; Johan Stranne; Anna Wallerstedt; Josefin Persson; Ulrica Wilderäng; Thordis Thorsteinsdottir; Ove Gustafsson; Mikael Lagerkvist; Thomas Jiborn; Eva Haglind; Peter Wiklund Journal: Eur Urol Date: 2014-10-28 Impact factor: 20.096
Authors: Jonathan J Chipman; Martin G Sanda; Rodney L Dunn; John T Wei; Mark S Litwin; Catrina M Crociani; Meredith M Regan; Peter Chang Journal: J Urol Date: 2013-09-25 Impact factor: 7.450
Authors: Kevin T McVary; Claus G Roehrborn; Jed C Kaminetsky; Stephen M Auerbach; Barton Wachs; Jay M Young; Anne Esler; Gregory D Sides; Bela S Denes Journal: J Urol Date: 2007-04 Impact factor: 7.450
Authors: Deborah R Kaye; M Eric Hyndman; Robert L Segal; Lynda Z Mettee; Bruce J Trock; Zhaoyong Feng; Li-Ming Su; Trinity J Bivalacqua; Christian P Pavlovich Journal: Urology Date: 2013-10-03 Impact factor: 2.649
Authors: Mauro Gacci; Alessandro Ierardi; Augusto Delle Rose; Stefano Tazzioli; Emanuele Scapaticci; Sandra Filippi; Mario Maggi; Giulio Nicita; Marco Carini; Francesco Montorsi Journal: J Sex Med Date: 2009-09-01 Impact factor: 3.802
Authors: H Padma-Nathan; A R McCullough; L A Levine; L I Lipshultz; R Siegel; F Montorsi; F Giuliano; G Brock Journal: Int J Impot Res Date: 2008-07-24 Impact factor: 2.896
Authors: Francesco Montorsi; Gerald Brock; Jay Lee; JoAnn Shapiro; Hendrik Van Poppel; Markus Graefen; Christian Stief Journal: Eur Urol Date: 2008-07-09 Impact factor: 20.096